文献速递类风湿关节炎

利用类风湿关节炎临床试验数据识别缓解预测因素与疾病活动模式的新方法

Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data.
PubMed 文献 · RMD Open · 2018-10-25

该研究整合18项试验中3290例未用生物制剂治疗的类风湿关节炎患者的个体数据,采用多重插补和随机效应逻辑回归识别6个月DAS28缓解的预测因素,并用潜类别混合模型刻画DAS28轨迹。结果显示总体缓解率为8.4%,初治与既往MTX暴露患者的预测因素不同,且两组均识别出三种不同的DAS28轨迹亚群。

要点

  • 初治与既往MTX暴露患者的缓解预测因素存在差异。
  • 两组患者中均识别出三种不同的DAS28轨迹亚群。
  • 总体缓解率为8.4%,初治患者为17%,既往暴露者为3.2%。

核心结论

  • 初治与既往MTX暴露患者的缓解预测因素不同,潜类别混合模型支持非生物制剂治疗反应的差异,两组均观察到三种不同轨迹。

研究设计与样本

  • 通过系统文献综述和联系英国上市许可持有人识别2002至2012年间完成的II期和III期临床试验,合并未用生物制剂组的匿名基线和随访个体参与者数据,采用多重插补处理缺失数据,随机效应逻辑回归识别6个月DAS28缓解预测因素,潜类别混合模型刻画DAS28随时间变化。

主要发现

  • 共纳入18项试验的3290例参与者,其中92%接受甲氨蝶呤(MTX)治疗。
  • 总体缓解率为8.4%(95%CI 7.4%至9.5%),初治早期RA患者为17%(95%CI 14.8%至19.4%),既往MTX暴露者为3.2%(95%CI 2.4%至4.3%)。
  • 既往MTX暴露患者中,较低基线DAS28和重新启用MTX与缓解相关。
  • 初治患者中,年轻、白人、男性、较好的功能和精神健康、较低基线DAS28及联合糖皮质激素与缓解相关。
  • 初治和既往MTX暴露患者中均识别出三种DAS28轨迹亚群,多个变量与亚群归属及亚群内DAS28水平相关。

关键数值与推荐

  • 缓解定义为6个月时DAS28达标。
  • 总体缓解率8.4%(95%CI 7.4%至9.5%),初治早期RA患者17%(95%CI 14.8%至19.4%),既往MTX暴露者3.2%(95%CI 2.4%至4.3%)。

临床怎么用

  • 初治与既往MTX暴露患者的缓解预测因素不同,评估病情时应考虑治疗暴露史。
  • 潜类别混合模型识别的三种DAS28轨迹亚群可用于设计未来RA试验和解读生物标志物研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To identify predictors of remission and disease activity patterns in patients with rheumatoid arthritis (RA) using individual participant data (IPD) from clinical trials. METHODS: Phase II and III clinical trials completed between 2002 and 2012 were identified by systematic literature review and contact with UK market authorisation holders. Anonymised baseline and follow-up IPD from non-biological arms were amalgamated. Multiple imputation was used to handle missing outcome and covariate information. Random effects logistic regression was used to identify predictors of remission, measured by the Disease Activity Score 28 (DAS28) at 6 months. Novel latent class mixed models characterised DAS28 over time. RESULTS: IPD of 3290 participants from 18 trials were included. Of these participants, 92% received methotrexate (MTX). Remission rates were estimated at 8.4%(95%CI 7.4%to9.5%) overall, 17%(95%CI 14.8%to19.4%) for MTX-naïve patients with early RA and 3.2% (95% CI 2.4% to 4.3%) for those with prior MTX exposure at entry. In prior MTX-exposed patients, lower baseline DAS28 and MTX reinitiation were associated with remission. In MTX-naïve patients, being young, white, male, with better functional and mental health, lower baseline DAS28 and receiving concomitant glucocorticoids were associated with remission. Three DAS28 trajectory subpopulations were identified in MTX-naïve and MTX-exposed patients. A number of variables were associated with subpopulation membership and DAS28 levels within subpopulations. CONCLUSIONS: Predictors of remission differed between MTX-naïve and prior MTX-exposed patients at entry. Latent class mixed models supported differential non-biological therapy response, with three distinct trajectories observed in both MTX-naïve and MTX-exposed patients. Findings should be useful when designing future RA trials and interpreting results of biomarker studies.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Novel methodology to discern predictors of remission and patterns of disease activity over time using rheumatoid arthritis clinical trials data. RMD Open. 2018. PMID: 30487994. doi:10.1136/rmdopen-2018-000721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。